dc.contributor.author | Lorente, D | |
dc.contributor.author | Omlin, A | |
dc.contributor.author | Zafeiriou, Z | |
dc.contributor.author | Nava-Rodrigues, D | |
dc.contributor.author | Pérez-López, R | |
dc.contributor.author | Pezaro, C | |
dc.contributor.author | Mehra, N | |
dc.contributor.author | Sheridan, E | |
dc.contributor.author | Figueiredo, I | |
dc.contributor.author | Riisnaes, R | |
dc.contributor.author | Miranda, S | |
dc.contributor.author | Crespo, M | |
dc.contributor.author | Flohr, P | |
dc.contributor.author | Mateo, J | |
dc.contributor.author | Altavilla, A | |
dc.contributor.author | Ferraldeschi, R | |
dc.contributor.author | Bianchini, D | |
dc.contributor.author | Attard, G | |
dc.contributor.author | Tunariu, N | |
dc.contributor.author | de Bono, J | |
dc.date.accessioned | 2016-09-05T12:01:15Z | |
dc.date.issued | 2016-12-01 | |
dc.identifier.citation | Clinical genitourinary cancer, 2016, 14 (6), pp. 485 - 493 | |
dc.identifier.issn | 1558-7673 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/96 | |
dc.identifier.eissn | 1938-0682 | |
dc.identifier.doi | 10.1016/j.clgc.2016.04.016 | |
dc.description.abstract | BACKGROUND: The urgent need for castration-resistant prostate cancer molecular characterization to guide treatment has been constrained by the disease's predilection to metastasize primarily to bone. We hypothesized that the use of clinical and imaging criteria could maximize tissue acquisition from bone marrow biopsies (BMBs). We aimed to develop a score for the selection of patients undergoing BMB. MATERIALS AND METHODS: A total of 115 BMBs were performed in 101 patients: 57 were included in a derivation set and 58 were used as the validation set. The clinical and laboratory data and prebiopsy computed tomography parameters (Hounsfield units [HUs]) were determined. A score for the prediction of biopsy positivity was developed from logistic regression analysis of the derivation set and tested in the validation set. RESULTS: Of the 115 biopsy specimens, 75 (62.5%) were positive; 35 (61.4%) in the test set and 40 (69%) in the validation set. On univariable analysis, hemoglobin (P = .019), lactate dehydrogenase (P = .003), prostate-specific antigen (P = .005), and mean HUs (P = .004) were selected. A score based on the LDH level (≥ 225 IU/L) and mean HUs (≥ 125) was developed in multivariate analysis and was associated with BMB positivity in the validation set (odds ratio, 5.1; 95% confidence interval, 1.9%-13.4%; P = .001). The area under the curve of the score was 0.79 in the test set and 0.77 in the validation set. CONCLUSION: BMB of the iliac crest is a feasible technique for obtaining tumor tissue for genomic analysis in patients with castration-resistant prostate cancer metastatic to the bone. A signature based on the mean HUs and LDH level can predict a positive yield with acceptable internal validity. Prospective studies of independent cohorts are needed to establish the external validity of the score. | |
dc.format | Print-Electronic | |
dc.format.extent | 485 - 493 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | CIG MEDIA GROUP, LP | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
dc.subject | Bone Marrow | |
dc.subject | Humans | |
dc.subject | Bone Neoplasms | |
dc.subject | Kallikreins | |
dc.subject | Prostate-Specific Antigen | |
dc.subject | L-Lactate Dehydrogenase | |
dc.subject | Tomography, X-Ray Computed | |
dc.subject | Biopsy | |
dc.subject | Bone Marrow Examination | |
dc.subject | Area Under Curve | |
dc.subject | Prospective Studies | |
dc.subject | Male | |
dc.subject | Prostatic Neoplasms, Castration-Resistant | |
dc.subject | Biomarkers, Tumor | |
dc.title | Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-04-22 | |
rioxxterms.versionofrecord | 10.1016/j.clgc.2016.04.016 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
rioxxterms.licenseref.startdate | 2016-12 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Clinical genitourinary cancer | |
pubs.issue | 6 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/18/19 Starting Cohort | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/18/19 Starting Cohort | |
pubs.publication-status | Published | |
pubs.volume | 14 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Cancer Biomarkers | |
icr.researchteam | Prostate Cancer Targeted Therapy Group | |
icr.researchteam | Treatment Resistance | |
dc.contributor.icrauthor | Miranda, Susana | |
dc.contributor.icrauthor | De Bono, Johann | |